Back

State of the art in drug therapy in chronic heart failure.

29 August 2016 (14:00 - 14:18)
Organised by:
Congress Presentation Part of: Drug therapy in heart failure Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Dirk van Veldhuisen

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr
Doctor G. Savarese (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)
Professor W. Kosmala (Wroclaw, PL)
Abstract Slides Video
Presentation thumbnail
Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors
Doctor P. Paren (Gothenburg, SE)
Abstract
Presentation thumbnail
Future direction for research in drug therapy.
Professor J. Teerlink (San Francisco, US)
Slides Video

Access the full session

Session thumbnail
Drug therapy in heart failure

The Event

Event poster

ESC Congress 2016

29 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Incremental efficacy of medical therapy for chronic heart failure with a reduced ejection fraction: a systematic review and network meta-analysis
1 July 2021
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
17 May 2025
thumbnail
Webinar
New 2021 HF guidelines - what is new for device therapies and how to optimally combine new HF drugs with ICD-CRTDs
16 February 2023
thumbnail
Congress Presentation
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.
12 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources